Valuation: CSL Limited

Market Cap 60.82B 53.06B 49.93B 45.5B 85.35B 5,827B 85.44B 598B 230B 2,969B 228B 223B 9,571B P/E 2027 *
20.9x
P/E 2028 * 18.9x
Enterprise Value 70B 61.06B 57.47B 52.36B 98.23B 6,706B 98.33B 689B 265B 3,416B 263B 257B 11,015B EV / Sales 2027 *
4.44x
EV / Sales 2028 * 4.27x
Free-Float
99.97%
Yield 2027 *
2.36%
Yield 2028 * 2.51%
1 day+1.54%
1 week+6.70%
Current month+3.92%
1 month+4.15%
3 months+53.28%
6 months+28.74%
Current year+3.27%
1 week 171.29
Extreme 171.29
178.48
1 month 165.79
Extreme 165.79
178.48
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 Free

Director

523 0.0001%
8/26/26 Free 317 0.0001% -
8/26/26 Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+1.54%+6.70%-10.12%-32.11% 59.78B
+1.70%+0.56%+34.83%-3.06% 78.37B
+12.27%+17.89%+585.18%+72.54% 61.5B
+0.29%-0.92%-10.95%+26.82% 46.53B
+1.92%+3.16%+4.33%+150.18% 45.5B
+1.66%+0.79%+53.73%-15.39% 31.84B
-0.53%+2.01%+44.05%+111.95% 25.4B
+6.00%+9.46%+11.24%+166.67% 21.43B
-0.76%+1.19%+57.98%+102.93% 15.77B
-0.05%-8.01%+27.13%+146.87% 13.02B
Average +1.22%+0.75%+79.74%+72.74% 39.92B
Weighted average by Cap. +1.27%+1.35%+105.57%+49.72%

Financials

2027 *2028 *
Net sales 15.77B 13.75B 12.94B 11.79B 22.12B 1,510B 22.15B 155B 59.74B 769B 59.22B 57.9B 2,481B 16.31B 14.23B 13.39B 12.2B 22.89B 1,563B 22.91B 160B 61.81B 796B 61.27B 59.9B 2,567B
Net income 2.82B 2.46B 2.32B 2.11B 3.96B 270B 3.97B 27.77B 10.7B 138B 10.6B 10.37B 444B 3.16B 2.76B 2.59B 2.36B 4.43B 303B 4.44B 31.07B 11.97B 154B 11.87B 11.6B 497B
Net Debt 9.18B 8.01B 7.53B 6.86B 12.88B 879B 12.89B 90.27B 34.77B 448B 34.47B 33.7B 1,444B 8.86B 7.73B 7.27B 6.62B 12.43B 848B 12.44B 87.11B 33.56B 432B 33.26B 32.52B 1,393B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-09-21 A$178.30 +1.54% 811,896
26-09-18 A$175.59 -1.11% 4,246,940
26-09-17 A$177.56 +1.81% 1,984,012
26-09-16 A$174.41 +0.09% 1,420,415
26-09-15 A$174.26 +1.57% 1,417,850
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
127.00USD
Average target price
126.28USD
Spread / Average Target
-0.57%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!